Alkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer
Chenliang Wang, Ming Zhu, Lei Bao, Vanina Toffessi Tcheuyap, James Brugarolas, Weibo Luo, Yingfei Wang · 2026
Read Alkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer by Chenliang Wang, Ming Zhu, Lei Bao, Vanina Toffessi Tcheuyap, James Brugarolas, Weibo Luo, Yingfei Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13471403.txt.
Description
Wang and co-authors searched for a way to make kidney tumors that resist PARP inhibitors, a class of DNA-repair-blocking drugs, vulnerable to them. Their 2026 laboratory study screened DNA-damaging alkylating agents for synergy with PARP blockade in clear cell renal cell carcinoma, the subtype behind about 80% of kidney cancers. Tumors with normal BRCA genes, usually unmoved by these inhibitors, were the specific target.
Two agents, temozolomide and streptozocin, pushed the PARP-1 enzyme into overdrive and created the opening the inhibitors exploit. The effect depended on SLFN11, a protein missing in about 45% of cancer cells, which marked which tumors responded. Combinations shrank tumors in mouse xenografts and in patient-derived tumor grafts, and every drug involved is already approved for cancer treatment.
Catalog record
| CREATOR | Chenliang Wang, Ming Zhu, Lei Bao, Vanina Toffessi Tcheuyap, James Brugarolas, Weibo Luo, Yingfei Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |